<?xml version='1.0' encoding='utf-8'?>
<document id="26491112"><sentence text="Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial."><entity charOffset="0-8" id="DDI-PubMed.26491112.s1.e0" text="Morphine" /></sentence><sentence text="The currently available data indicate a drug-drug interaction between morphine and oral P2Y12 receptor inhibitors, when administered together"><entity charOffset="70-78" id="DDI-PubMed.26491112.s2.e0" text="morphine" /></sentence><sentence text=" The aim of this trial was to assess the influence of infused morphine on pharmacokinetics and pharmacodynamics of ticagrelor and its active metabolite (AR-C124910XX) in patients with acute myocardial infarction"><entity charOffset="62-70" id="DDI-PubMed.26491112.s3.e0" text="morphine" /></sentence><sentence text="" /><sentence text="In a single-centre, randomized, double-blind trial, patients were assigned in a 1:1 ratio to receive intravenously either morphine (5 mg) or placebo, followed by a 180 mg loading dose of ticagrelor"><entity charOffset="122-130" id="DDI-PubMed.26491112.s5.e0" text="morphine" /><entity charOffset="187-197" id="DDI-PubMed.26491112.s5.e1" text="ticagrelor" /><pair ddi="false" e1="DDI-PubMed.26491112.s5.e0" e2="DDI-PubMed.26491112.s5.e0" /><pair ddi="false" e1="DDI-PubMed.26491112.s5.e0" e2="DDI-PubMed.26491112.s5.e1" /></sentence><sentence text=" Pharmacokinetics was determined with liquid chromatography tandem mass spectrometry and ticagrelor antiplatelet effects were measured with up to three different platelet function tests: vasodilator-stimulated phosphoprotein phosphorylation assay, multiple electrode aggregometry and VerifyNow" /><sentence text=" The pharmacokinetic and pharmacodynamic assessment was performed in 70 patients (35 in each study group)" /><sentence text=" Morphine lowered the total exposure to ticagrelor and its active metabolite by 36% (AUC(0-12): 6307 vs"><entity charOffset="1-9" id="DDI-PubMed.26491112.s8.e0" text="Morphine" /></sentence><sentence text=" 9791 ng h/mL; P = 0" /><sentence text="003), and 37% (AUC(0-12): 1503 vs" /><sentence text=" 2388 ng h/mL; P = 0" /><sentence text="008), respectively, with a concomitant delay in maximal plasma concentration of ticagrelor (4 vs"><entity charOffset="80-90" id="DDI-PubMed.26491112.s12.e0" text="ticagrelor" /></sentence><sentence text=" 2 h; P = 0" /><sentence text="004)" /><sentence text=" Multiple regression analysis showed that lower AUC(0-12) values for ticagrelor were independently associated with the administration of morphine (P = 0"><entity charOffset="137-145" id="DDI-PubMed.26491112.s15.e0" text="morphine" /></sentence><sentence text="004) and the presence of ST-segment elevation myocardial infarction (P = 0" /><sentence text="014)" /><sentence text=" All three methods of platelet reactivity assessment showed a stronger antiplatelet effect in the placebo group and a greater prevalence of high platelet reactivity in patients receiving morphine"><entity charOffset="187-195" id="DDI-PubMed.26491112.s18.e0" text="morphine" /></sentence><sentence text="" /><sentence text="Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction"><entity charOffset="0-8" id="DDI-PubMed.26491112.s20.e0" text="Morphine" /></sentence><sentence text=" ClinicalTrials" /><sentence text="gov Identifier: NCT02217878" /><sentence text="" /></document>